Daniel R. Casper
VP, Information Technology
We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
We’re advancing muscle biology-driven treatments for diseases characterized by compromised muscle function, muscle weakness, and fatigue.
We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA.
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors.
Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance.
Bonnie joined Cytokinetics in January 2014 as our Senior Vice President of Regulatory Affairs and Compliance.
Prior to joining Cytokinetics, Bonnie served as Vice President of Regulatory and Quality at Metabolex, Inc. (now CymaBay Therapeutics). From 2001 to 2006 she served as Vice President of Regulatory and Quality at Genitope Corp. From 1995 to 2001, she held regulatory positions at Roche Global Development, a division of F. Hoffman-La Roche Ltd., including Vice President and Regulatory Site Head in Palo Alto, California. Prior to that, she held regulatory positions of increasing responsibility at Syntex Corporation. She began her career as an analytical chemist at Procter and Gamble Co. in Cincinnati, Ohio.
Dr. Charpentier obtained her Ph.D. in Biology from the University of Houston. She has served on the Board of Directors of the American Chemical Society, including as Chair of the Board.
Bonnie and her husband, Lee, share a passion for science-based community outreach, including bringing hands-on science activities to homeless youth. When Bonnie’s two sons are home everyone can be found outdoors at the beach, hiking or biking, or in the kitchen experimenting with recipes old and new.